Bone and haematological problems: Edited by Allan Lipton and James R. BerensonDenosumab: benefits of RANK ligand inhibition in cancer patientsLipton, Allana,b; Jacobs, Iraa,bAuthor Information aPenn State Hershey Medical Center, Hershey, Pennsylvania bAmgen Inc., Thousand Oaks, California, USA Correspondence to Allan Lipton, MD, Penn State Hershey Medical Center, 500 University Drive, Hershey, PA 17033-0850, USATel: +1 717 531 8677; fax: +1 717 531 5076; e-mail: firstname.lastname@example.org Current Opinion in Supportive and Palliative Care: September 2011 - Volume 5 - Issue 3 - p 258-264 doi: 10.1097/SPC.0b013e328349731c Buy Metrics Abstract Purpose of review RANK ligand (RANKL) plays a central role in the cancer-induced bone destruction that results from bone metastasis. The RANKL inhibitor denosumab was recently approved for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. This review summarizes recent findings of the effects of RANKL inhibition and denosumab in the cancer setting. Recent findings Preclinical data show that RANKL inhibition in combination with antitumor therapies has additive effects on preventing skeletal tumor progression. Preclinical breast cancer models also suggest RANKL may be involved in primary tumorigenesis and establishment of metastases in bone and other tissues. Pivotal clinical trial data with denosumab in advanced cancer patients across tumor types showed it was superior (breast and prostate) or noninferior trending toward superior (solid tumors/multiple myeloma) to zoledronic acid, in reducing the risk of developing an SRE and demonstrated a favorable safety profile. Denosumab has also demonstrated efficacy in the treatment of giant cell tumor of bone. Summary Denosumab offers an important new treatment option for patients with solid tumors and bone metastases. The efficacy of RANKL inhibition with denosumab in other disease states in the cancer setting continues to be evaluated. © 2011 Lippincott Williams & Wilkins, Inc.